Article: TAXOTERE (docetaxel) CLEARED FOR USE AS A TREATMENT FOR PATIENTS WITH ADVANCED BREAST CANCER IN UNITED STATES

COLLEGEVILLE, Pa., May 15 /PRNewswire/ -- Rhone-Poulenc Rorer Inc. (NYSE: RPR) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its new anticancer agent, Taxotere (docetaxel) for Injection Concentrate, as a treatment for patients who have locally advanced or metastatic (spreading) breast cancer which has progressed during anthracycline-based therapy or has relapsed during anthracycline-based adjuvant therapy. Approximately two out of three breast cancer patients treated with chemotherapy in the United States receive anthracyclines at some point in the treatment of their disease.

"We are pleased with the FDA ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!